Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Kristian Humer Biography and Net Worth

CFO of Viridian Therapeutics

Kristian joined Viridian as Chief Financial Officer and Chief Business Officer in 2021. He also serves on the board of directors at Sensei Biotherapeutics, Inc. Prior to joining Viridian, Kristian served for 11 years at Citigroup, most recently as a Managing Director, helping to lead the biopharma coverage effort within their healthcare investment banking group. In this role, Kristian worked with a variety of biopharma management teams and boards on a range of strategic matters, including capital and financing strategy, executing equity and equity linked financings, and leading buy- and sell-side transactions. Prior to Citigroup, Kristian held roles at Lehman Brothers, UBS and Merrill Lynch.

Kristian holds an MBA from Duke University’s Fuqua School of Business and a BA degree in Accounting & Economics from the University of Reading.

How do I contact Kristian Humer?: The corporate mailing address for Mr. Humer and other Viridian Therapeutics executives is 6200 LOOKOUT ROAD, BOULDER CO, 80301. Viridian Therapeutics can also be reached via phone at (617) 272-4600 and via email at [email protected]. Learn More on Kristian Humer's contact information.
Has Kristian Humer been buying or selling shares of Viridian Therapeutics?: Kristian Humer has not been actively trading shares of Viridian Therapeutics in the last ninety days. Learn More on Kristian Humer's trading history.
Who are Viridian Therapeutics' active insiders?: Viridian Therapeutics' insider roster includes Kristian Humer (CFO), and Jonathan Violin (Insider). Learn More on Viridian Therapeutics' active insiders.
Are insiders buying or selling shares of Viridian Therapeutics?: During the last twelve months, Viridian Therapeutics insiders bought shares 4 times. They purchased a total of 2,102,590 shares worth more than $40,616,302.00. The most recent insider tranaction occured on September, 27th when COO Thomas W Beetham bought 5,000 shares worth more than $117,050.00. Insiders at Viridian Therapeutics own 0.7% of the company. Learn More about insider trades at Viridian Therapeutics.
Information on this page was last updated on 9/27/2024.

Kristian Humer Insider Trading History at Viridian Therapeutics

Kristian Humer Buying and Selling Activity at Viridian Therapeutics

Viridian Therapeutics Company Overview

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $20.14

$19.65

$21.77

50 Day Range

MA: $22.64

$14.19

$25.71

2 Week Range

Now: $20.14

$11.40

$27.20

Volume

1,833,127 shs

Average Volume

1,020,517 shs

Market Capitalization

$1.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

This company will win the AI race

From Porter & Company | Ad